Terms: = Lung cancer AND NPM1, NPM, 4869, ENSG00000181163, P06748, B23, MGC104254 AND Treatment
39 results:
1. Nucleophosmin promotes lung adenocarcinoma cell proliferation, migration and invasion by activating the EGFR/MAPK signaling pathway.
Li M; Wu R; Zhu D; Wang L; Liu S; Wang R; Deng C; Zhang S; Chen M; Lu R; Zhu H; Mo M; Luo Z
Oncol Rep; 2023 Jun; 49(6):. PubMed ID: 37165929
[TBL] [Abstract] [Full Text] [Related]
2. DNA Sequencing to Detect Residual Disease in Adults With Acute Myeloid Leukemia Prior to Hematopoietic Cell Transplant.
Dillon LW; Gui G; Page KM; Ravindra N; Wong ZC; Andrew G; Mukherjee D; Zeger SL; El Chaer F; Spellman S; Howard A; Chen K; Auletta J; Devine SM; Jimenez Jimenez AM; De Lima MJG; Litzow MR; Kebriaei P; Saber W; Weisdorf DJ; Hourigan CS
JAMA; 2023 Mar; 329(9):745-755. PubMed ID: 36881031
[TBL] [Abstract] [Full Text] [Related]
3. Reassessing pharmacogenomic cell sensitivity with multilevel statistical models.
Ploenzke M; Irizarry R
Biostatistics; 2023 Oct; 24(4):901-921. PubMed ID: 35277956
[TBL] [Abstract] [Full Text] [Related]
4. npm1 Is a Prognostic Biomarker Involved in Immune Infiltration of lung Adenocarcinoma and Associated With m6A Modification and Glycolysis.
Liu XS; Zhou LM; Yuan LL; Gao Y; Kui XY; Liu XY; Pei ZJ
Front Immunol; 2021; 12():724741. PubMed ID: 34335635
[TBL] [Abstract] [Full Text] [Related]
5. Early nucleolar responses differentiate mechanisms of cell death induced by oxaliplatin and cisplatin.
Sutton EC; DeRose VJ
J Biol Chem; 2021; 296():100633. PubMed ID: 33819479
[TBL] [Abstract] [Full Text] [Related]
6. Minimal Residual Disease Monitoring Using a 3'ALK Universal Probe Assay in ALK-Positive Anaplastic Large-Cell Lymphoma: ddPCR, an Attractive Alternative Method to Real-Time Quantitative PCR.
Quelen C; Grand D; Sarot E; Brugières L; Sibon D; Pradines A; Laurent C; Brousset P; Lamant L
J Mol Diagn; 2021 Feb; 23(2):131-139. PubMed ID: 33246076
[TBL] [Abstract] [Full Text] [Related]
7. Epigenetic CRISPR Screens Identify
Li F; Ng WL; Luster TA; Hu H; Sviderskiy VO; Dowling CM; Hollinshead KER; Zouitine P; Zhang H; Huang Q; Ranieri M; Wang W; Fang Z; Chen T; Deng J; Zhao K; So HC; Khodadadi-Jamayran A; Xu M; Karatza A; Pyon V; Li S; Pan Y; Labbe K; Almonte C; Poirier JT; Miller G; Possemato R; Qi J; Wong KK
Cancer Res; 2020 Sep; 80(17):3556-3567. PubMed ID: 32646968
[TBL] [Abstract] [Full Text] [Related]
8. Dactinomycin in acute myeloid leukemia with npm1 mutations.
Beziat G; Tavitian S; Bertoli S; Huguet F; Largeaud L; Luquet I; Vergez F; Rieu JB; Bories P; Delabesse E; Récher C
Eur J Haematol; 2020 Sep; 105(3):302-307. PubMed ID: 32452083
[TBL] [Abstract] [Full Text] [Related]
9. Development of a Brigatinib degrader (SIAIS117) as a potential treatment for ALK positive cancer resistance.
Sun N; Ren C; Kong Y; Zhong H; Chen J; Li Y; Zhang J; Zhou Y; Qiu X; Lin H; Song X; Yang X; Jiang B
Eur J Med Chem; 2020 May; 193():112190. PubMed ID: 32179332
[TBL] [Abstract] [Full Text] [Related]
10. Lorlatinib treatment Elicits Multiple On- and Off-Target Mechanisms of Resistance in ALK-Driven cancer.
Redaelli S; Ceccon M; Zappa M; Sharma GG; Mastini C; Mauri M; Nigoghossian M; Massimino L; Cordani N; Farina F; Piazza R; Gambacorti-Passerini C; Mologni L
Cancer Res; 2018 Dec; 78(24):6866-6880. PubMed ID: 30322862
[TBL] [Abstract] [Full Text] [Related]
11. [Preliminary study of exon sequence in pneumoconiosis and pneumoconiosis complicated with lung cancer using high-throughput sequencing technology].
Jiang MF; Li L; Wang Z; Zhang CL; Zhang H
Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi; 2017 Nov; 35(11):801-806. PubMed ID: 29316748
[No Abstract] [Full Text] [Related]
12. Crizotinib in Combination with Everolimus Synergistically Inhibits Proliferation of Anaplastic Lymphoma Kinase‒Positive Anaplastic Large Cell Lymphoma.
Xu W; Kim JW; Jung WJ; Koh Y; Yoon SS
Cancer Res Treat; 2018 Apr; 50(2):599-613. PubMed ID: 28675026
[TBL] [Abstract] [Full Text] [Related]
13. Anaplastic lymphoma kinase (ALK) inhibitors in the treatment of ALK-driven lung cancers.
Roskoski R
Pharmacol Res; 2017 Mar; 117():343-356. PubMed ID: 28077299
[TBL] [Abstract] [Full Text] [Related]
14. cancer upregulated gene 2 induces epithelial-mesenchymal transition of human lung cancer cells via TGF-β signaling.
Kaowinn S; Kim J; Lee J; Shin DH; Kang CD; Kim DK; Lee S; Kang MK; Koh SS; Kim SJ; Chung YH
Oncotarget; 2017 Jan; 8(3):5092-5110. PubMed ID: 27974707
[TBL] [Abstract] [Full Text] [Related]
15. Accurate Medicine: Indirect Targeting of npm1-Mutated AML.
Hourigan CS; Aplan PD
Cancer Discov; 2016 Oct; 6(10):1087-1089. PubMed ID: 27698101
[TBL] [Abstract] [Full Text] [Related]
16. TKI sensitivity patterns of novel kinase-domain mutations suggest therapeutic opportunities for patients with resistant ALK+ tumors.
Amin AD; Li L; Rajan SS; Gokhale V; Groysman MJ; Pongtornpipat P; Tapia EO; Wang M; Schatz JH
Oncotarget; 2016 Apr; 7(17):23715-29. PubMed ID: 27009859
[TBL] [Abstract] [Full Text] [Related]
17. 1-Benzyl-2-methyl-3-indolylmethylene barbituric acid derivatives: Anti-cancer agents that target nucleophosmin 1 (npm1).
Penthala NR; Ketkar A; Sekhar KR; Freeman ML; Eoff RL; Balusu R; Crooks PA
Bioorg Med Chem; 2015 Nov; 23(22):7226-33. PubMed ID: 26602084
[TBL] [Abstract] [Full Text] [Related]
18. Development and validation of a novel assay to identify radiosensitizers that target nucleophosmin 1.
Penthala NR; Crooks PA; Freeman ML; Sekhar KR
Bioorg Med Chem; 2015 Jul; 23(13):3681-6. PubMed ID: 25922180
[TBL] [Abstract] [Full Text] [Related]
19. Activity of second-generation ALK inhibitors against crizotinib-resistant mutants in an npm-ALK model compared to EML4-ALK.
Fontana D; Ceccon M; Gambacorti-Passerini C; Mologni L
Cancer Med; 2015 Jul; 4(7):953-65. PubMed ID: 25727400
[TBL] [Abstract] [Full Text] [Related]
20. treatment Efficacy and Resistance Mechanisms Using the Second-Generation ALK Inhibitor AP26113 in Human npm-ALK-Positive Anaplastic Large Cell Lymphoma.
Ceccon M; Mologni L; Giudici G; Piazza R; Pirola A; Fontana D; Gambacorti-Passerini C
Mol Cancer Res; 2015 Apr; 13(4):775-83. PubMed ID: 25421750
[TBL] [Abstract] [Full Text] [Related]
[Next]
